In the news | 20th Aug 2021
Three Reasons Biopharma Companies Can't Afford to Miss the Digital Revolution
Industry expert, Claire Hill, comments on the top three reasons biopharma companies simply can’t afford to wait any longer to join the digital revolution.
In the biopharmaceutical industry, there’s no shortage of data—the issue organizations more often face is how to capture data in ways that derive insight from it. As more and more companies are now recognizing, a fundamentally different approach is needed to realize the strategic benefits of data in making exciting and transformative new applications, such as digital twins, a reality.
Ensuring product, process and patient data integrity and traceability throughout the BioPharmaceutical lifecycle in the era of personalized medicine
The BioPharma industry is facing a multitude of challenging external trends, from the growth in personalized medicine to supply chain disruptions and more.
European Biomanufacturing Summit 2023
Come and join us at booth 130 in Amsterdam, to learn how an innovative tech transfer approach can revolutionize drug manufacturing in the pharmaceutical industry.
IDBS events roundup: Q1 highlights and Q2 events
IDBS associates had the opportunity to attend some events in Q1 and attendees were eager to see, hear and learn more about what’s happening in the industry.
How to improve time-to-value using GxP computer systems
Explore the benefits of GxP computer systems to improve time-to-value so that companies can speed up the development and manufacture of life-saving drugs.